Matrixyl
A palmitoylated collagen-fragment pentapeptide used topically to mimic matrikine signaling and stimulate dermal collagen synthesis for anti-aging.
Matrixyl (palmitoyl pentapeptide-4; Pal-KTTKS) is a fatty acid-conjugated synthetic pentapeptide derived from the pro-collagen I sequence, developed by Sederma as a cosmetic active ingredient. It works by mimicking matrikine signaling — the natural response when collagen fragments are generated during matrix turnover — to prompt fibroblasts to replenish structural proteins such as collagen I, collagen IV, fibronectin, and hyaluronic acid. The palmitoyl chain enhances penetration through the lipid-rich stratum corneum. A published split-face clinical study reported measurable reductions in facial line depth and skin roughness, though effects are modest and the peptide is regulated as a cosmetic ingredient rather than a drug.
Class
Synthetic palmitoylated pentapeptide (matrikine cosmetic active)
Half-life
N/A (topical application)
Routes
Topical
Category
Skin, Hair & Cosmetic
Researched benefits
What it's studied for
Collagen I and III synthesis
The KTTKS matrikine sequence signals dermal fibroblasts to upregulate production of collagen I and III, the key structural proteins that support skin firmness and thickness. This anabolic effect is the primary proposed mechanism behind its anti-aging use.
Fibronectin and extracellular matrix support
Beyond collagen, Matrixyl is proposed to stimulate fibroblast production of collagen IV, fibronectin, and hyaluronic acid, supporting overall dermal matrix integrity and hydration.
Wrinkle and fine-line reduction
A 12-week split-face randomized controlled trial reported significant reductions in wrinkles and fine lines versus placebo by both quantitative image analysis and expert grader assessment, providing clinical validation of its collagen-stimulating action.
Improved skin firmness and smoothness
Profilometry data from photoaged facial skin showed measurable reductions in line depth and skin roughness, consistent with improved structural integrity, though effects are modest by pharmaceutical standards.
Mechanism
How it works
Matrixyl is a fatty acid-conjugated synthetic pentapeptide derived from the pro-collagen I sequence. It works by mimicking matrikine signaling — the natural cellular response that occurs when collagen fragments are generated during extracellular matrix turnover, which triggers fibroblasts to increase production of structural proteins to replenish the matrix. By presenting the KTTKS collagen fragment, Matrixyl effectively signals the skin that repair is needed.
The palmitoyl chain is a lipid modification that enhances penetration through the lipid-rich stratum corneum, improving delivery of the otherwise poorly-absorbed peptide into the dermis. Once absorbed, the KTTKS matrikine sequence is proposed to stimulate fibroblast production of collagen I, collagen IV, fibronectin, and hyaluronic acid. Some sources describe this as procollagen production via the MAPK pathway and TGF-beta receptor signaling on fibroblasts, while noting the anabolic response occurs without hormonal or receptor-agonist activity.
Matrixyl 3000 is a second-generation Sederma formulation that combines the original Matrixyl (Pal-KTTKS) with palmitoyl tetrapeptide-7 (Pal-GQPR). The two peptides address different sides of collagen turnover: Pal-KTTKS drives new collagen synthesis, while palmitoyl tetrapeptide-7 is proposed to inhibit overproduction of IL-6, an inflammatory interleukin linked to accelerated collagen breakdown and glycation-related aging. Together the combination targets both the anabolic (synthesis) and catabolic (degradation) aspects of matrix aging.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Original Matrixyl (Pal-KTTKS)
- Dose
- ~3 ppm peptide in formulation
- Frequency
- Once to twice daily
- Timing
- Applied to clean skin, typically morning and/or evening
- Duration
- 8-12 weeks for visible effect; ongoing for maintenance
- Route
- Topical
The concentration used in the pivotal clinical trial was 3 ppm topical Pal-KTTKS. Considered sufficient for preventative anti-aging use.
Matrixyl 3000 (combination)
- Dose
- 4-8% of the combined proprietary peptide solution
- Frequency
- Once to twice daily
- Timing
- Applied to clean skin
- Duration
- 8-12 weeks of daily application
- Route
- Topical
Combines Pal-KTTKS with palmitoyl tetrapeptide-7. Considered the stronger formulation for photoaged skin with existing collagen deficit. Actual peptide content within the Sederma dilution is lower than the stated solution percentage.
- Matrixyl is used topically only — it is a cosmetic active incorporated into serums, creams, and moisturizers, not an injectable.
- Consistent daily application over 8-12 weeks is required before measurable changes in line depth and roughness are typically seen; cosmetic wrinkle-depth reductions reported are in the range of 15-25% over that window.
- The original Matrixyl is generally considered adequate for preventative use, while Matrixyl 3000 is preferred for photoaged skin with existing collagen loss.
- Effects are modest by pharmaceutical standards; independent replication of the published clinical findings is limited.
Evidence
Research & clinical studies (1)
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin
In a 12-week double-blind, placebo-controlled, split-face randomized trial of 93 women, topical Pal-KTTKS at 3 ppm significantly reduced wrinkles and fine lines versus placebo by both quantitative image analysis and expert grader assessment, clinically validating its collagen-stimulating signal-peptide mechanism.
PMID 18492182Combinations
Stacking & blends
Matrixyl 3000
Address both collagen synthesis and collagen breakdown for photoaged skin
Pal-KTTKS stimulates new collagen synthesis while palmitoyl tetrapeptide-7 inhibits IL-6-driven inflammatory collagen degradation, targeting both the anabolic and catabolic sides of matrix aging. Cited industry data reports 15-25% wrinkle-depth reduction over 8-12 weeks.
Safety
Side effects & considerations
Contraindications & cautions
- None established for topical use
Matrixyl is generally considered lower risk in research and cosmetic contexts, with no established contraindications for topical use. Individual response varies; as with any topical, patch testing is prudent for sensitive skin.
FAQ
Matrixyl — common questions
What is Matrixyl?
Matrixyl (palmitoyl pentapeptide-4; Pal-KTTKS) is a fatty acid-conjugated synthetic pentapeptide derived from the pro-collagen I sequence, developed by Sederma as a cosmetic active ingredient. It stimulates dermal matrix synthesis by mimicking matrikine signaling — the natural response that triggers fibroblasts to replenish structural proteins when collagen fragments are generated during matrix turnover.
What is Matrixyl primarily studied for?
It is primarily studied for collagen I and III synthesis, fibronectin increase, wrinkle reduction, and skin firmness.
How does the palmitoyl chain help?
The palmitoyl (fatty acid) chain enhances penetration through the lipid-rich stratum corneum, improving delivery of the otherwise poorly-absorbed KTTKS peptide into the dermis where it can signal fibroblasts.
What is the difference between Matrixyl and Matrixyl 3000?
The original Matrixyl is just Pal-KTTKS and mainly stimulates collagen synthesis; Matrixyl 3000 adds palmitoyl tetrapeptide-7 (Pal-GQPR), which is proposed to inhibit IL-6-driven collagen breakdown. Matrixyl 3000 is considered the stronger formulation for photoaged skin with existing collagen deficit, while the original is sufficient for preventative use.
What does the research show about Matrixyl?
In a 12-week double-blind, placebo-controlled, split-face randomized trial of 93 women, topical Pal-KTTKS at 3 ppm significantly reduced wrinkles and fine lines versus placebo by both quantitative image analysis and expert grader assessment. Effects are modest and independent replication is limited.
What are the side effects of Matrixyl?
There are no established contraindications for topical use, and it is generally considered lower risk. Individual response varies — consult a qualified professional and patch test if you have sensitive skin.
Is Matrixyl FDA-approved?
No. Matrixyl is regulated as a cosmetic ingredient, not a drug. It has no FDA drug approval, no NDA or IND, and requires no prescription. It should be understood as a cosmetically active ingredient rather than a clinically validated therapeutic.
